In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories

How Sanofi Is Embracing AI In Everyday Operations

Senior management at the Paris-headquartered drugmaker tell In Vivo about how embracing artificial intelligence has enhanced its ability to accelerate drug discovery, improve clinical trial design and revolutionize its manufacturing and supply processes.

 

 

Artificial Intelligence Innovation

Kiji Takes Flight With Off-The-Shelf Stem Cells

Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.

Podcast: The Colorful Landscape Of Therapeutic Psychedelics

Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.

Data Spotlight

Deals Shaping The Industry, August 2024

An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.

Execs On The Move: August 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

US Adalimumab Outlook Brightens At Mid-Point Of 2024

The latest figures on uptake of rivals to AbbVie's Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator after an initially slow start in 2023.

Deal Volume Up, Value Down During The First Half

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

See All
Growth

2025’s Therapy Area Growth Drivers And Brakes: Part Three

The final instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on mood disorders, immunodeficiency, viral infections, and blood cell disorders.

US Approvals Of Novel Drugs Set To Hit 10-Year High In 2025

But 2024 will see a lull between two strong years.

Biopharma’s Fastest Growing Technology Groups

The next six years will see rapid growth in several newer pharmaceutical technology groups. In this article In Vivo examines the technologies currently forecast to see highest rates of growth, as well as those with the most actual sales growth out to 2030.

Balancing Up The Clinician Burnout-AI Equation

The medical industry must scale up to meet rising demand for care with fewer clinicians. Artificial intelligence can take care to the next levels of volume and quality – and in equity of delivery, insists the company, Annalise.ai.

See All
Innovation

Kiji Takes Flight With Off-The-Shelf Stem Cells

Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.

Podcast: The Colorful Landscape Of Therapeutic Psychedelics

Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.

How Sanofi Is Embracing AI In Everyday Operations

Senior management at the Paris-headquartered drugmaker tell In Vivo about how embracing artificial intelligence has enhanced its ability to accelerate drug discovery, improve clinical trial design and revolutionize its manufacturing and supply processes.

Biophotonics Sheds A New Light On Diagnostics

Photonics enhances diagnostic imaging accuracy and speeds up diagnoses, says Antanus Laurutis, CEO of Altechna.

See All
Leadership

Kiji Takes Flight With Off-The-Shelf Stem Cells

Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.

AstraZeneca Believes Size Matters In Amyloidosis

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.

Execs On The Move: August 2024

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

'Not Going With The Crowd’: Mapping Gene Potential With ProFound Therapeutics

John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.

See All
Market Access

US Generics Players Enjoy Calmer Waters

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. 

Market Prices Or Political Expediency? Amgen’s US Lawsuit Seen As Litmus Test

As the US struggles to contain the cost of prescription medicines, a growing number of state governments are trying to take matters into their own hands and believe prescription drug affordability boards could be the answer.

The Future Of Medical Evidence Generation

Boston Consulting Group and senior pharma industry executives take a broad look at the challenges and opportunities for medical affairs evidence generation with multiple modalities.

Market Access Strategies: Nudging Negotiations Along

Deals in pharma to secure market access are now business as usual. More deals will be needed in future too. Yet they take time and are not easy to successfully conclude. Could nudging the negotiations help?

See All
Market Intelligence

Podcast: The Colorful Landscape Of Therapeutic Psychedelics

Datamonitor Healthcare analysts and podcast co-hosts Flora Mackay and Emma Wille discuss the complicated development of therapeutic psychedelics. They dwell on FDA involvement and advisory committees, alongside adverse event reporting and ethical concerns.

Deals Shaping The Industry, August 2024

An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.

US Generics Players Enjoy Calmer Waters

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. 

Deals in Depth: August 2024

Six $1bn+ alliances were penned in August. In the top alliance by deal value, ImmuneOnco Biopharmaceuticals licensed Instil Bio global rights (excluding China, Taiwan, Macau, and Hong Kong) to develop and commercialize its PD-L1xVEGF bispecific antibody IMM2510 and the next-generation anti-CTLA-4 antibody IMM27M. The deal could be worth over $2bn. The candidates have potential in treating advanced solid tumors.

See All
Recent Stories

AstraZeneca Believes Size Matters In Amyloidosis

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.

Deals Shaping The Industry, August 2024

An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.

US Generics Players Enjoy Calmer Waters

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. 

Final Chance To Have Your Say: Take Our Reader Survey This Week

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

How Sanofi Is Embracing AI In Everyday Operations

Senior management at the Paris-headquartered drugmaker tell In Vivo about how embracing artificial intelligence has enhanced its ability to accelerate drug discovery, improve clinical trial design and revolutionize its manufacturing and supply processes.

Biophotonics Sheds A New Light On Diagnostics

Photonics enhances diagnostic imaging accuracy and speeds up diagnoses, says Antanus Laurutis, CEO of Altechna.

First Stage Of UK NHS Review 2024: Darzi Delivers His Early Verdict

Can the new UK government's raw enthusiasm for NHS reform be a catalyst for real change where countless past attempts to address the national provider's shortcomings have failed to hit the spot? And what might the 10-year plan mean for medtech?

Deals in Depth: August 2024

Six $1bn+ alliances were penned in August. In the top alliance by deal value, ImmuneOnco Biopharmaceuticals licensed Instil Bio global rights (excluding China, Taiwan, Macau, and Hong Kong) to develop and commercialize its PD-L1xVEGF bispecific antibody IMM2510 and the next-generation anti-CTLA-4 antibody IMM27M. The deal could be worth over $2bn. The candidates have potential in treating advanced solid tumors.

2025’s Therapy Area Growth Drivers And Brakes: Part Three

The final instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on mood disorders, immunodeficiency, viral infections, and blood cell disorders.

US Approvals Of Novel Drugs Set To Hit 10-Year High In 2025

But 2024 will see a lull between two strong years.

Focus On Cardio-Oncology, Clinical Trends And AI At ESC 2024

Updated guidance on the risk of cardiotoxicity in patients following cancer treatment is expected soon. The first consensus guidelines were issued eight years ago. AI is being used for early risk identification, Philips said during the European Society of Cardiology congress 2024.

UsernamePublicRestriction

Register